Role of P-glycoprotein in pharmacokinetics: clinical implications.
about
Clinically and pharmacologically relevant interactions of antidiabetic drugsUpdate and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitisDrug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical dataFlavonoids: modulators of brain function?Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast CancerP-Glycoprotein Transport of Neurotoxic PesticidesEffects on P-Glycoprotein Expression after Blood-Brain Barrier Disruption Using Focused Ultrasound and Microbubbles.In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2)Modulation of cytochrome P450 metabolism and transport across intestinal epithelial barrier by ginger biophenolicsSplenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male ratsRecent advances in pharmacokinetic extrapolation from preclinical data to humans.Telithromycin-induced digoxin toxicity and electrocardiographic changes.Pharmacokinetic interactions of drugs with St John's wort.Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions.Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.Differential bidirectional transfer of indinavir in the isolated perfused human placenta.Clinical significance of ABCB1 genotyping in oncology.Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patientsP-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.Budesonide in the treatment of inflammatory bowel disease.Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.Herbal modulation of P-glycoprotein.Pharmacokinetics of methadone.Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.Multidrug resistance gene 1 C1236T polymorphism and susceptibility to leukemia: A meta-analysisSucralose, a synthetic organochlorine sweetener: overview of biological issuesTissue distribution of naringenin conjugated metabolites following repeated dosing of naringin to rats.Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro-cognitive performance.Human pharmacogenomic variations and their implications for antifungal efficacy.Determination of fexofenadine in Hank's balanced salt solution by high-performance liquid chromatography with ultraviolet detection: application to Caco-2 cell permeability studies.A novel systems pharmacology model for herbal medicine injection: a case using Reduning injection.Clinical relevance of P-glycoprotein in drug therapy.Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer CellsIdentification of a Cryptic Bacterial Promoter in Mouse (mdr1a) P-Glycoprotein cDNA.Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice.The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance.
P2860
Q26752468-A92C23C1-9246-4E3F-9AA9-A1695F968C29Q26799723-3B2D1534-4727-4946-8E30-F4BCCE03CF81Q28084970-B1837D55-AEDE-486C-AC14-3080BBB85E92Q28281453-01535630-1169-4401-8AC5-6D193D35E78DQ28383510-B2FD0272-814B-4C8D-99C8-FB46F0172FFAQ28389145-73386E24-0AA1-48E1-ABC7-72E2F7A11767Q28468445-ED85ACDA-467C-4523-8346-D46FE9674EABQ28540667-31BBBB96-43E7-4875-8EC0-4409E078118AQ28543201-C53ACE67-556D-418E-8412-71EEE278C4B4Q28570040-D594B7F3-FF6D-4CBD-AAD7-78F1ABA6E50FQ31049599-D36CD640-F00F-457F-B983-CFFE3E328E9FQ33153871-97404F98-1FB2-4DCB-8830-A792E6794CCCQ33204911-406FAF75-B065-4470-8BD8-F39C157876D3Q33456441-42136C58-7FFB-418D-974E-078365FB9CB5Q33559358-56E02FD2-89D0-447E-958C-4257465F9830Q33857508-E3EE3D54-AEC2-43B3-B45E-D97CFD41F9D6Q33951034-3201C413-41C8-4416-8CBA-D3AA101499E3Q34141845-C5725370-230A-41BB-8D7D-C757009B5173Q34171741-E9E4FF91-D644-47EC-A305-1240B0E350A3Q34203594-B57F3ACE-E99F-4AC6-97C2-C986C6C01B85Q34273853-D68B0986-21B4-40FD-BA14-A4C6E0F9CA95Q34312035-7A9E86B7-B529-4596-A5CC-630BA9380349Q34487284-832BB02B-7D41-4B1F-9163-DE676226FA3AQ34589333-D5D56CED-E267-440D-B172-282946EDE4F1Q34607510-9375D428-9297-4999-AF11-DB86A5C215E9Q34657381-DC82D7F3-506D-4C8E-942C-7E5535DA739FQ34691857-337D06F7-7157-4336-ADF3-7F5F7CD05B9EQ34769942-E31E4E63-FF92-4DF0-A8C5-9BF98B081FF1Q35070838-1C4EF09A-EECE-4F94-BD11-CFBC18D43D82Q35232517-CEA519C0-18E8-453D-96AF-F01E4971D0D9Q35389260-343A57FC-6962-4BE0-BAAA-FFFA1E8CAB59Q35620664-A28CD3D1-C748-4CAE-AA67-4E6A296F656DQ35670917-7AD08E03-F811-4A86-B47F-5F1C21956C19Q35756130-B14BC680-AEF1-48FC-B834-B6DE080C815BQ35774851-7A88F807-7E05-4527-AC17-7758D29C51B3Q35800047-605B667B-F6CA-4A5D-9008-4D128EE627B0Q35826102-AE82E5CA-1172-474C-B46B-95C8A80A4584Q35827580-E58BA2C0-E36A-4AB1-B77E-573BC9D01981Q35860275-AE0038BB-3E40-4132-87BC-F17A3BE0A5CDQ35956193-1E184E41-2C19-4294-B52B-312224DDA8AD
P2860
Role of P-glycoprotein in pharmacokinetics: clinical implications.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Role of P-glycoprotein in pharmacokinetics: clinical implications.
@ast
Role of P-glycoprotein in pharmacokinetics: clinical implications.
@en
type
label
Role of P-glycoprotein in pharmacokinetics: clinical implications.
@ast
Role of P-glycoprotein in pharmacokinetics: clinical implications.
@en
prefLabel
Role of P-glycoprotein in pharmacokinetics: clinical implications.
@ast
Role of P-glycoprotein in pharmacokinetics: clinical implications.
@en
P1476
Role of P-glycoprotein in pharmacokinetics: clinical implications.
@en
P2093
Jiunn H Lin
Masayo Yamazaki
P356
10.2165/00003088-200342010-00003
P577
2003-01-01T00:00:00Z
P5875
P6179
1001234191